Journal Logo

A STUDY OF TRANSFUSION RELATED ADVERSE EVENTS IN FAYOUM UNIVERSITY HOSPITALS, EGYPT: HEMOVIGILENCE INITIATIVE

PB2446

Ezzat, G.1; Abdelrazik, A.2; Elshafei, S.3; Abbas, Mansour M.3; El Hassan, Abou S.3

doi: 10.1097/01.HS9.0000568244.62280.16
Publication Only: Transfusion medicine
Free

1Clinical Pathology, Fayoum University, Cairo

2Fayoum University, Cairo, Egypt

3clinical pathology, Fayoum University, Cairo, Egypt

Back to Top | Article Outline

Background:

Hemovigilance is an adverse reaction monitoring system to improve the safety and quality of blood transfusion. Identification of the adverse reactions and their risk factors would help in taking appropriate steps to reduce their incidence.

Back to Top | Article Outline

Aims:

To identify the transfusion related adverse events and their rates for benchmarking purposes in Fayoum University Hospitals (FUH) for implementation of the hemovigilance system.

Back to Top | Article Outline

Methods:

The study was conducted in FUH, from May 2016 to April 2017. All patients receiving transfusion therapy and all blood donors were included. All the adverse events related to transfusion of blood and blood products were recorded.

Back to Top | Article Outline

Results:

A total of 8687 blood components were issued to 3292 recipients from 8300 donors. Ninety Nine donor reactions were reported, with a rate of (1.19%), vasovagal attacks being the most common complication (91.8 %). Thirty Six (1.09 %) recipients adverse reactions were reported to the blood bank. The most common reaction observed in recipients was allergic reaction (47.2%) followed by febrile non- hemolytic transfusion reaction (36.1%).

Back to Top | Article Outline

Summary/Conclusion:

Data related to adverse transfusion reactions in developing countries for benchmarking purposes are rare in literature. The use of transfusion related adverse reactions to build the hemovigilance system facilitates its development and allows areas requiring improvement to be tracked and identified.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.